04.10-11.24-HST-Han

Conference Video|Duration: 30:43
April 10, 2024
  • Video details

    With the explosive growth in cell and gene therapy during the last decade, manufacturing of high quality gene delivery vectors (AAVs and Lentiviruses) now poses a critical bottleneck for the industry. In this presentation, I will introduce a continuous, intensified HEK293 bioprocessing platforms enabled by high-throughput microfluidic systems. Membrane-free vector harvesting by high-throughput inertial microfluidic system could be used to achieve intensified perfusion culture of host cells, and generated vectors are harvested continuously in order to minimize the loss and degradation. We believe that intensification of upstream vector bioprocessing would lead to a significant increase in productivity and reduction in reagents as well as GMP space needs, eventually resulting in reduction in the cost of gene and cell therapies of the future.

  • Video details

    With the explosive growth in cell and gene therapy during the last decade, manufacturing of high quality gene delivery vectors (AAVs and Lentiviruses) now poses a critical bottleneck for the industry. In this presentation, I will introduce a continuous, intensified HEK293 bioprocessing platforms enabled by high-throughput microfluidic systems. Membrane-free vector harvesting by high-throughput inertial microfluidic system could be used to achieve intensified perfusion culture of host cells, and generated vectors are harvested continuously in order to minimize the loss and degradation. We believe that intensification of upstream vector bioprocessing would lead to a significant increase in productivity and reduction in reagents as well as GMP space needs, eventually resulting in reduction in the cost of gene and cell therapies of the future.